catch the disease much earlier, when more treatment options are available
Pancreatic cancer has long been a disease of cruel timing — diagnosed too late, treated too little, survived by too few. Researchers at Oregon Health & Science University have developed a blood test called PAC-MANN that may rewrite that timing, detecting molecular signatures of the disease from a near-invisible drop of blood in under an hour. At a cost of less than a penny per sample and with 98 percent accuracy in distinguishing cancer from healthy patients, the test carries not just clinical promise but a rare quality in modern medicine: the possibility of reaching those who have historically been left out of early detection altogether.
- Pancreatic cancer kills with such consistency partly because no practical early-detection tool has existed — PAC-MANN directly challenges that decades-long gap.
- The test's near-microscopic sample size and sub-penny cost create urgency around equity: rural clinics and underserved communities could finally access screening that was previously out of reach.
- When combined with the existing CA 19-9 marker, PAC-MANN achieved 85% accuracy at early stages — a meaningful leap over current methods that routinely miss the disease until it is too late to operate.
- Researchers observed protease activity dropping after surgery, suggesting the test could monitor treatment response in real time and allow clinicians to adjust therapy before outcomes deteriorate.
- An investigator-initiated clinical trial with high-risk patients is now being planned at OHSU's Knight Cancer Institute, the next critical step before PAC-MANN can enter standard screening protocols.
Pancreatic cancer has long carried a grim reputation: by the time most patients receive a diagnosis, the disease has already spread beyond the reach of surgery. The five-year survival rate hovers near 10 percent, a number that has barely moved in decades. Researchers at Oregon Health & Science University believe a new tool — a magnetic nanosensor blood test called PAC-MANN — may finally change the timing of that encounter.
The test detects shifts in protease activity, a molecular marker of pancreatic ductal adenocarcinoma, from just eight microliters of blood. It runs in 45 minutes and costs less than a penny per sample. In a 350-patient study, PAC-MANN correctly identified pancreatic cancer 98 percent of the time, and when paired with the existing CA 19-9 marker, it detected early-stage disease with 85 percent accuracy — a significant improvement over current methods.
Jared Fischer, who led the research at OHSU's Knight Cancer Institute, framed the work plainly: the goal is to give clinicians a tool that finds the disease when treatment options still exist. Lead author Jose L. Montoya Mira stressed the accessibility dimension — unlike conventional liquid biopsies requiring specialized equipment and large blood volumes, PAC-MANN could be deployed in rural clinics and community health centers where traditional screening is impractical.
The test also showed a second capability: protease activity declined after surgery, suggesting PAC-MANN could track treatment response in real time and help clinicians adjust course as needed. Fischer and Montoya are now planning clinical trials with high-risk patients. If validated, PAC-MANN could transform pancreatic cancer from a disease caught too late into one met early enough to matter.
Pancreatic cancer has a reputation for arriving too late. By the time most patients learn they have it, the disease has already spread beyond the reach of surgery or chemotherapy. The five-year survival rate hovers around 10 percent—a grim statistic that has barely budged in decades. Now researchers at Oregon Health & Science University believe they may have found a way to catch it earlier, when treatment still stands a fighting chance.
The tool is called PAC-MANN, shorthand for a magnetic nanosensor that detects changes in protease activity—a molecular signature of pancreatic ductal adenocarcinoma, the most common and lethal form of the disease. The test works on a blood sample so small it would barely fill a drop: eight microliters. It takes 45 minutes to run and costs less than a penny per sample. In a study of 350 patients—some with cancer, some at high risk, some healthy—the test correctly identified pancreatic cancer 98 percent of the time. When paired with an existing marker called CA 19-9, it detected early-stage cancer with 85 percent accuracy, a significant improvement over current screening methods that lack the sensitivity to catch disease in its earliest phases.
Jared Fischer, an assistant professor at OHSU's Knight Cancer Institute, led the research team. "The problem with pancreatic cancer is that we often catch it too late," he said. "Our goal with PAC-MANN is to give clinicians a tool that can detect the disease much earlier, when more treatment options are available and there is a better chance of survival." The work was published in Science Translational Medicine and represents years of collaboration between engineers and biologists who wanted to build something practical—not just accurate, but usable in places where specialty labs don't exist.
Jose L. Montoya Mira, the study's lead author and a research engineer at OHSU, emphasized the accessibility angle. Current liquid biopsy tests require large volumes of blood and specialized equipment. PAC-MANN needs neither. "Our test could be used for people at high risk of pancreatic cancer, which is not targeted by current tests," Montoya said. "It allows for a more robust and less invasive screening, unlike an endoscopic ultrasound and other liquid biopsy tests that require large volumes of blood, thus allowing our test to be performed more frequently for earlier detection." The simplicity matters. A test that costs a fraction of a cent and runs in under an hour could be deployed in rural clinics, community health centers, and underserved regions where traditional screening is impractical or impossible.
The test does more than detect cancer. In the study, researchers observed that protease activity decreased after surgery, suggesting PAC-MANN could track whether treatment is working in real time. This opens a second door: not just catching cancer earlier, but monitoring patients as they move through therapy and adjusting course if needed. "If we can track a patient's response to therapy in real time, we can make better treatment decisions and improve outcomes," Fischer said.
The next phase is already underway. Montoya and Fischer are planning an investigator-initiated clinical trial with high-risk patients in collaboration with OHSU's Knight Cancer Institute. If those trials confirm what the initial study suggests, PAC-MANN could reshape how pancreatic cancer screening works—moving it from a tool that arrives too late to one that catches disease when patients still have options. For a cancer that has resisted progress for so long, that would be a meaningful shift.
Citas Notables
The problem with pancreatic cancer is that we often catch it too late. Our goal with PAC-MANN is to give clinicians a tool that can detect the disease much earlier, when more treatment options are available and there is a better chance of survival.— Jared Fischer, assistant professor, OHSU Knight Cancer Institute
This test could easily be used in rural and underserved settings, where traditional tests are not or cannot be used.— Jose L. Montoya Mira, lead author and research engineer, OHSU
La Conversación del Hearth Otra perspectiva de la historia
Why does pancreatic cancer stay so deadly compared to other cancers?
It's partly biology and partly timing. The pancreas sits deep in the abdomen, so tumors grow quietly without causing symptoms until they're already large. By then they've often spread to the liver or other organs. And the current blood test, CA 19-9, is good at telling you how sick someone is, but it can't reliably catch the disease early enough to matter.
So this new test is sensitive enough to catch it before symptoms show up?
That's the promise. In their study, PAC-MANN found early-stage cancer 85 percent of the time when combined with CA 19-9. That's a real gap-filler. But it's not a magic bullet yet—they still need to prove it works in a larger, real-world population.
The cost angle seems almost as important as the accuracy. Why?
Because a test that costs a penny and needs eight microliters of blood can be run anywhere. A rural clinic in Montana can do it. A community health center in an underserved neighborhood can do it. You can screen people more often without breaking the budget. That's how you actually change outcomes—not just in wealthy medical centers, but everywhere.
Can it tell you if treatment is working?
Yes. They saw protease activity drop after surgery, which suggests the test could track whether a patient is responding to therapy in real time. That means doctors could adjust treatment faster instead of waiting weeks for imaging to show whether something worked.
What's the timeline before this becomes available to patients?
They're starting a clinical trial with high-risk patients now. If that validates the initial findings, it could move toward clinical use. But these things take time. You're probably looking at a few years minimum before it's standard screening.